Immunotherapy News and Research

Latest Immunotherapy News and Research

12-chemokine gene signature can predict presence of lymph node-like structures in MM

Researchers at Moffitt Cancer Center have discovered a unique immune gene signature that can predict the presence of microscopic lymph node-like structures in metastatic melanoma. The presence of these immune structures, the researchers said, appears to be associated with better survival and may indicate the possibility of selecting patients for immunotherapy based solely on the immune-related makeup of their tumors as an approach to personalized medicine.

25 Oct 2012

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

CEL-SCI Corporation announced today that an interim review of the safety data from its open label, randomized, controlled, pivotal Phase III study of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy by an Independent Data Monitoring Committee (IDMC) raised no safety concerns.

23 Oct 2012

Hutchinson Center's cancer epidemiologist to receive IARC Medal of Honor

Cancer epidemiologist John Potter, M.D., Ph.D., a senior adviser in the Public Health Sciences Division at Fred Hutchinson Cancer Research Center, has been selected to receive a medal of honor from the World Health Organization's International Agency for Research on Cancer for his research contributions in nutrition, diet and cancer.

20 Oct 2012

ACT TIL therapy effective in treating metastatic melanoma

Researchers at Moffitt Cancer Center have carried out a clinical trial in which patients with metastatic melanoma were given chemotherapy and an immunotherapy of adoptive cell transfer (ACT) with tumor infiltrating lymphocytes (TIL).

19 Oct 2012

Weill Cornell Medical College researcher wins 2012 William B. Coley Award

Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and provost for medical affairs of Cornell University, is a winner of the 2012 William B. Coley Award for Distinguished Research in Basic Immunology from the Cancer Research Institute for her outstanding achievements in immunology and cancer research.

19 Oct 2012

Research to determine how genes contribute to Type 1 diabetes

Diabetes is a chronic, debilitating disease which affects nearly 26 million Americans. As many as three million people have Type 1 diabetes or juvenile diabetes that usually occurs in children or young adults.

19 Oct 2012

Scientists look to use natural killer cells to target common form of liver cancer

Scientists at the University of Southampton are to investigate the best way to use natural killer cells (NK) to target the most common form of liver cancer. NK cells are able to directly kill cancer in the body and stimulate other cells in the immune system to help attack cancer.

14 Oct 2012

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

NewLink Genetics Corporation announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients with borderline resectable or locally advanced unresectable pancreatic cancer.

10 Oct 2012

Chemotherapy plus immunotherapy can enhance anti-tumor effects in patients with advanced cancer

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida and Tianjin Medical University Cancer Institute and Hospital in China have discovered that combining chemotherapy drugs and immunotherapy cancer vaccines results in an enhanced anti-tumor effect.

10 Oct 2012

CRI, MedImmune partner to advance cancer immunotherapy research

The Cancer Research Institute (CRI), the Ludwig Institute for Cancer Research and MedImmune, the global biologics arm of AstraZeneca, today announced that they have signed a collaboration agreement to advance the research of immunotherapy in cancer.

10 Oct 2012

NIH awards $2.1M grant to study possible ways to fight cancer

A professor with the University of Houston Cullen College of Engineering has won a $2.1 million grant to study the best ways to modify human immune cells to fight against cancer.

6 Oct 2012

Sublingual immunotherapy highly effective for chronic allergy and asthma sufferers

Could it be that those with allergic rhinitis (hay fever) and childhood nasal allergies can finally get a break from their allergies and their allergy shots? Chicago's leading allergy, asthma, and immunology expert, Dr. Brian Rotskoff, who treats a large number of Chicago pediatric allergy patients, is happy to say, "Yes!"

5 Oct 2012

Circassia commences ToleroMune phase 3 trial in cat allergen-induced rhinoconjunctivitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune cat allergy treatment for cat allergen-induced rhinoconjunctivitis.

4 Oct 2012

BHGI sponsors global summit on international breast health

For women with breast cancer in low- and middle-resource countries and other medically underserved areas around the world, the need for supportive care and the consideration of quality-of-life issues are often overlooked.

2 Oct 2012

Novel therapy shows promise in treating multiple myeloma following stem cell transplants

A novel therapy in the early stages of development at Virginia Commonwealth University Massey Cancer Center shows promise in providing lasting protection against the progression of multiple myeloma following a stem cell transplant by making the cancer cells easier targets for the immune system.

2 Oct 2012

Administering immunotherapy for three years can reduce allergies, asthma in children

When children suffer from dust mite induced allergies and asthma, finding relief can seem impossible. While there isn't a complete cure for childhood respiratory allergies, researchers have found that long term control of allergic asthma can occur after only three years of allergy shots.

1 Oct 2012

Researchers identify how p110delta molecule controls the body's inflammatory responses

Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism.

1 Oct 2012

September issue of JNCCN publishes two prostate cancer articles

Julio M. Pow-Sang, M.D., chair of Moffitt Cancer Center's Department of Genitourinary Oncology, and colleagues have published two prostate cancer articles in the September issue of JNCCN - The Journal of the National Comprehensive Cancer Network. The articles review and clarify recent updates made to the National Comprehensive Cancer Network's (NCCN) guidelines for the screening and treatment of prostate cancer.

29 Sep 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

UCSD receives NCI grant to continue research into chronic lymphocytic leukemia

An international consortium of scientists studying chronic lymphocytic leukemia (CLL), based at the University of California, San Diego School of Medicine, has been awarded a 5-year, $20 million grant by the National Cancer Institute, part of the National Institutes of Health.

28 Sep 2012

Immunotherapy News and Research

Latest Immunotherapy News and Research

12-chemokine gene signature can predict presence of lymph node-like structures in MM

Interim results from CEL-SCI's Multikine Phase III study on head and neck cancer

Hutchinson Center's cancer epidemiologist to receive IARC Medal of Honor

ACT TIL therapy effective in treating metastatic melanoma

Weill Cornell Medical College researcher wins 2012 William B. Coley Award

Research to determine how genes contribute to Type 1 diabetes

Scientists look to use natural killer cells to target common form of liver cancer

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

Chemotherapy plus immunotherapy can enhance anti-tumor effects in patients with advanced cancer

CRI, MedImmune partner to advance cancer immunotherapy research

NIH awards $2.1M grant to study possible ways to fight cancer

Sublingual immunotherapy highly effective for chronic allergy and asthma sufferers

Circassia commences ToleroMune phase 3 trial in cat allergen-induced rhinoconjunctivitis

BHGI sponsors global summit on international breast health

Novel therapy shows promise in treating multiple myeloma following stem cell transplants

Administering immunotherapy for three years can reduce allergies, asthma in children

Researchers identify how p110delta molecule controls the body's inflammatory responses

September issue of JNCCN publishes two prostate cancer articles

Synta announces results from ganetespib Phase 2b trial on NSCLC

UCSD receives NCI grant to continue research into chronic lymphocytic leukemia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Immunotherapy News and Research

Latest Immunotherapy News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in